Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
PaperCitations, authors & open-access status
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,629 citations, 2021 year and green oa status.
1,629
Citations
2021
Year
green
OA Status